Axsome Therapeutics (AXSM) Price & Analysis

Compare

2,314 Followers

AXSM Stock Chart & Stats

$183.22

-$0.23(-0.27%)

At close: Jan 08 4:00 PM EST

$183.22

-$0.23(-0.27%)

Day’s Range― - ―

52-Week Range$86.99 - $191.50

Previous CloseN/A

Volume140.83K

Average Volume (3M)761.01K

Market Cap

$9.29B

Enterprise Value$9.14B

Total Cash (Recent Filing)$325.27M

Total Debt (Recent Filing)$218.60M

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Feb 23, 2026

EPS Estimate

-0.69

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.94

Shares Outstanding50,412,640

10 Day Avg. Volume598,305

30 Day Avg. Volume761,015

Financial Highlights & Ratios

PEG Ratio-1.03

Price to Book (P/B)71.10

Price to Sales (P/S)10.51

P/FCF Ratio-31.50

Enterprise Value/Market Cap0.98

Enterprise Value/Revenue16.29

Enterprise Value/Gross Profit17.73

Enterprise Value/Ebitda-43.06

Forecast

1Y Price Target

$209.54

Price Target Upside14.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)0.58

Revenue Forecast (FY)$1.00B

Bulls Say, Bears Say

Bulls Say

Commercial PerformanceAuvelity sales modestly beating analyst forecasts, combined with rising total prescriptions and improved growth metrics, supports upgraded revenue expectations and analyst Buy ratings.

Pipeline DevelopmentInitiation of pivotal Phase 3 dosing for AXS-14 and planned NDA pathways for AXS-12, coupled with Orphan Drug designation for narcolepsy, bolster the pipeline and lower development risk.

RegulatoryFDA acceptance of the supplemental application for Auvelity with priority review increases the likelihood of approval in Alzheimer's agitation and could enable meaningful label expansion beyond depression.

Bears Say

Clinical Consistency RiskThe ADVANCE-2 study missing its primary endpoint increases uncertainty around the consistency of clinical evidence and complicates prospects for broader label expansion of AXS-05.

Product Launch ExecutionSymbravo's weak new-prescription uptake and underperformance versus expectations signal difficulties scaling the migraine launch and constrain near-term revenue contribution.

Revenue VolatilityLarge week-to-week prescription swings and holiday-related declines for marketed drugs create short-term revenue volatility and make it harder for investors to assess durable demand trends.

Axsome Therapeutics News

Axsome Therapeutics price target raised to $195 from $190 at TD Cowen

TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $190 and keeps a...

15d ago

AXSM

Axsome Therapeutics management to meet with Oppenheimer

Dinner Meeting to be held in New York on January 27 hosted by Oppenheimer. Published first on TheFly...

23d ago

AXSM

Axsome Therapeutics price target raised to $219 from $212 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $219 from $212...

23d ago

AXSM

Axsome Therapeutics price target raised to $260 from $200 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $260 from $200 and keeps a...

24d ago

AXSM

Axsome Therapeutics price target raised to $223 from $148 at Piper Sandler

Piper Sandler raised the firm’s price target on Axsome Therapeutics (AXSM) to $223 from $148 and keeps an...

28d ago

AXSM

Axsome Therapeutics initiate FORWARD Phase 3 trial of AXS-14

Axsome Therapeutics (AXSM) announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14...

29d ago

AXSM

Reaffirming Axsome Therapeutics as a Buy on Robust Commercial Growth and Advancing Late‑Stage Pipeline, With a Raised $260 Price Target

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Axsome Therapeutics. The associated price target...

24d ago

AXSM

Axsome Therapeutics price target raised to $209 from $157 at Baird

Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $209 from $157 and keeps an Outperform...

1M ago

AXSM

Axsome Therapeutics price target raised to $193 from $157 at Wells Fargo

Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $193 from $157 and keeps an...

1M ago

AXSM

Axsome Therapeutics: Strong Commercial Execution and De-Risked Pipeline Support Buy Rating and Long-Term Growth

William Blair analyst Myles Minter has reiterated their bullish stance on AXSM stock, giving a Buy rating yesterday....

1M ago

AXSM

Buy Rating on Axsome Therapeutics Backed by Strong Auvelity and Sunosi Outperformance Despite Slower Symbravo Ramp

Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics yesterday and set a price target of...

1M ago

AXSM

Axsome Therapeutics Reports Strong Preliminary 2025 Revenue Growth

Axsome Therapeutics ( ($AXSM) ) has provided an announcement. On January 12, 2026, Axsome Therapeutics reported preliminary, unaudited...

1M ago

AXSM

Axsome Therapeutics reports preliminary Q4 revenue $196M, consensus $187.02M

Based on preliminary unaudited financial information, Axsome expects total product revenue to be approximately $196.0 million for the...

1M ago

AXSM

Axsome Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded Axsome Therapeutics (AXSM) to Equal Weight from Overweight with a price target of $204, up...

1M ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $86.99 and its highest was $191.50 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $9.29B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Feb 23, 2026 which is in 10 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on Nov 03, 2025. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.861 by -$0.079.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.69.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 50,412,640 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.861. Following the earnings report the stock price went up 0.563%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Axsome Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-275.50%

Trailing 12-Months

Asset Growth

19.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Axsome Therapeutics reported strong revenue growth and product performance, supported by strategic commercial execution and a robust R&D pipeline. However, increased expenses and ongoing net losses present financial challenges.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$209.54

▲(14.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"101":"$101","141":"$141","181":"$181","221":"$221","261":"$261"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$260.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":209.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$209.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":153,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$153.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[101,141,181,221,261],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.88,191.58153846153846,197.28307692307692,202.98461538461538,208.68615384615384,214.3876923076923,220.08923076923077,225.79076923076923,231.4923076923077,237.19384615384615,242.89538461538461,248.59692307692308,254.29846153846154,{"y":260,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.88,187.7,189.51999999999998,191.34,193.16,194.98,196.79999999999998,198.62,200.44,202.26,204.07999999999998,205.9,207.72,{"y":209.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,185.88,183.35076923076923,180.82153846153847,178.2923076923077,175.7630769230769,173.23384615384614,170.70461538461538,168.17538461538462,165.64615384615385,163.1169230769231,160.5876923076923,158.05846153846153,155.52923076923076,{"y":153,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >